Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT2003 in advanced colorectal carcinoma
NCT00405561Phase 3Terminated
- Sponsor
- Auron Healthcare GmbH
- Start
- Oct 2006
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of AMT 2003 in colorectal carcinoma (CRC), sponsored by Auron Healthcare GmbH. Primary endpoint: Progression free survival rate at 18 weeks. Started Oct 2006; status: terminated.
02
Drugs
AMT 2003
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT00405561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00405561.